This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Barbhaiya, R H
Right arrow Articles by Pittman, K A
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Barbhaiya, R H
Right arrow Articles by Pittman, K A

 Previous Article  |  Next Article 

Antimicrob Agents Chemother. 1987 January; 31(1): 55-59

High-pressure liquid chromatographic analysis of BMY-28142 in plasma and urine.

R H Barbhaiya, S T Forgue, W C Shyu, E A Papp and K A Pittman

ABSTRACT

A high-pressure liquid chromatographic assay was developed for the quantitative analysis of a new cephalosporin, BMY-28142, in plasma and urine. The plasma method involved protein precipitation with acetonitrile and trichloroacetic acid followed by extraction of the acetonitrile into dichloromethane. After centrifugation, the organic phase was discarded, the aqueous solution was injected into a reverse-phase column, and peaks were detected at 280 nm. The urine method involved dilution of a urine sample with sodium acetate buffer (pH 4.25) and direct injection into the high-pressure liquid chromatography system. The assay validation data indicate that the assays for BMY-28142 in plasma and urine were specific, accurate, and reproducible. The analytical methods were applied to the determination of protein binding in human serum and to a pharmacokinetic study in rats. The results of the protein-binding study indicated that BMY-28142 was 16.3% bound to human serum proteins. In the pharmacokinetic study in rats, the maximum level in plasma of 38.7 micrograms/ml was achieved at 2.33 h after administration of a subcutaneous dose of 100 mg/kg. The levels in the plasma then declined with an elimination half-life of about 0.56 h. The mean values for the steady-state volume of distribution and total body clearance were 0.46 liters/kg and 11.9 ml/min per kg, respectively. The 0- to 24-h excretion of intact BMY-28142 in urine accounted for 88.6% of the dose.

Antimicrob Agents Chemother. 1987 January; 31(1): 55-59




This article has been cited by other articles:

  • Ambrose, P. G., Bhavnani, S. M., Jones, R. N. (2003). Pharmacokinetics-Pharmacodynamics of Cefepime and Piperacillin- Tazobactam against Escherichia coli and Klebsiella pneumoniae Strains Producing Extended-Spectrum {beta}-Lactamases: Report from the ARREST Program. Antimicrob. Agents Chemother. 47: 1643-1646 [Abstract] [Full Text]  
  • Bugnon, D., Giannoni, E., Majcherczyk, P., Glauser, M. P., Moreillon, P. (2002). Pitfalls in Cefepime Titration from Human Plasma: Plasma- and Temperature-Related Drug Degradation In Vitro. Antimicrob. Agents Chemother. 46: 3654-3656 [Abstract] [Full Text]  
  • Malone, R. S., Fish, D. N., Abraham, E., Teitelbaum, I. (2001). Pharmacokinetics of Cefepime during Continuous Renal Replacement Therapy in Critically Ill Patients. Antimicrob. Agents Chemother. 45: 3148-3155 [Abstract] [Full Text]  
  • Delcenserie, R., Dellion-Lozinguez, M. P., Yzet, T., Lepointe, B., Hary, L., Badoui, R., Verhaeghe, P., Andrejak, M., Dupas, J. L. (2001). Pancreatic concentrations of cefepime. J Antimicrob Chemother 47: 711-713 [Abstract] [Full Text]  
  • Sampol, E., Jacquet, A., Viggiano, M., Bernini, V., Manelli, J.-C., Lacarelle, B., Durand, A. (2000). Plasma, urine and skin pharmacokinetics of cefepime in burns patients. J Antimicrob Chemother 46: 315-317 [Abstract] [Full Text]  
  • Mimoz, O., Leotard, S., Jacolot, A., Padoin, C., Louchahi, K., Petitjean, O., Nordmann, P. (2000). Efficacies of Imipenem, Meropenem, Cefepime, and Ceftazidime in Rats with Experimental Pneumonia Due to a Carbapenem-Hydrolyzing beta -Lactamase-Producing Strain of Enterobacter cloacae. Antimicrob. Agents Chemother. 44: 885-890 [Abstract] [Full Text]  
  • Bonapace, C. R., White, R. L., Friedrich, L. V., Norcross, E. D., Bosso, J. A. (1999). Pharmacokinetics of Cefepime in Patients with Thermal Burn Injury. Antimicrob. Agents Chemother. 43: 2848-2854 [Abstract] [Full Text]  
  • Lipman, J., Wallis, S. C., Rickard, C. (1999). Low Plasma Cefepime Levels in Critically Ill Septic Patients: Pharmacokinetic Modeling Indicates Improved Troughs with Revised Dosing. Antimicrob. Agents Chemother. 43: 2559-2561 [Abstract] [Full Text]  
  • Mimoz, O., Elhelali, N., Leotard, S., Jacolot, A., Laurent, F., Samii, K., Petitjean, O., Nordmann, P. (1999). Treatment of experimental pneumonia in rats caused by a PER-1 extended-spectrum {beta}-lactamase-producing strain of Pseudomonas aeruginosa. J Antimicrob Chemother 44: 91-97 [Abstract] [Full Text]  
  • Mimoz, O., Jacolot, A., Leotard, S., Hidri, N., Samii, K., Nordmann, P., Petitjean, O. (1998). Efficacies of Cefepime, Ceftazidime, and Imipenem Alone or in Combination with Amikacin in Rats with Experimental Pneumonia Due to Ceftazidime-Susceptible or -Resistant Enterobacter cloacae Strains. Antimicrob. Agents Chemother. 42: 3304-3308 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»